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background: In the large-scale CHAMPION PHOENIX trial, cangrelor significantly reduced peri-procedural and 30-day ischemic events in patients 
(pts) undergoing PCI. We sought to evaluate the incidence and impact of stent thrombosis (ST) among this large cohort.
Methods: Angiographic analysis was performed by an independent core laboratory in 10 939 pts. ST was defined as the occurrence of either 
intra-procedural ST (IPST) or ARC defined ST (definite or probable). Adverse events were adjudicated by an independent, blinded clinical events 
committee.
results: ST occurred in 120 (1.1%) and 175 (1.6%) pts at 48 hours and 30 days, respectively. The occurrence of ST at 48 hours and 30 days was 
associated with a marked increase in 30-day mortality (OR [95%CI] = 15.3 [8.6, 27.2], p<0.001 and 55.2 [36.6, 83.3] p<0.001 respectively). 
The occurrence of each type of ST, individually, was also associated with an increase in mortality (IPST: 17.4 [8.4, 36.1], p<0.001, ARC acute ST: 
43.3 [18.1, 103.5], p<0.001, ARC sub-acute ST: 189.1, [107.9, 331.4], p<0.001). Cangrelor was associated with a significant reduction in 48-hour 
(0.8% vs. 1.4%, p=0.01) and 30-day ST (1.3% vs. 1.9%, p=0.01), compared with clopidogrel, and its effect was consistent on different subsets of ST 
(Figure).
conclusion: In the large-scale CHAMPION PHOENIX trial, the occurrence of ST was strongly associated with increased mortality. Cangrelor use 
resulted in a significant reduction in ST, with consistent effects on intra-procedural, acute, and sub-acute ST.
 
